XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat ...

Not everyone with IgA nephropathy will need steroids, but for some, these medications can help protect kidney function. Here’s a closer look at the benefits, risks, and side effects.

VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therape ...

Budoprutug receives FDA Fast Track status for primary membranous nephropathy after phase 1b data demonstrate clinical activity and safety.

Based on this, this study retrospectively analyzes the clinical testing data of patients with diabetic nephropathy and those with simple diabetes mellitus to investigate the predictive value of ...

A once-daily oral tablet, sparsentan is fully approved to reduce proteinuria in patients ages 8 and older with FSGS who do ...

The optimal management of asymptomatic serological reactivation in lupus nephritispatients has been unclear, so a trial tested preemptive treatment.

High blood sugar can complicate symptoms of Peyronie’s disease, and getting it under control may help you see improvements.

Travere Therapeutics received approval from the Food and Drug Administration for a treatment for a rare kidney disorder. The biopharmaceutical company said Monday the approval is for its Filspari drug ...

David Novak and his late wife Wendy — who died from Type 1 diabetes complications in 2024 — spent their lives advocating for ...

Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not ...